Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger

PHASE3TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 29, 2021

Primary Completion Date

December 22, 2022

Study Completion Date

December 22, 2022

Conditions
Thrombotic Microangiopathy
Interventions
BIOLOGICAL

Ravulizumab

Body weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.

OTHER

Placebo

Matching placebo

OTHER

Best Supportive Care

Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).

Trial Locations (97)

1070

Research Site, Brussels

1200

Research Site, Belgium

2650

Research Site, Edegem

3000

Research Site, Leuven

4000

Research Site, Liège

6591

Research Site, Seoul

10032

Research Site, New York

10595

Research Site, Valhalla

11217

Research Site, Taipei

15212

Research Site, Pittsburgh

18014

Research Site, Granada

19107

Research Site, Philadelphia

20007

Research Site, Washington D.C.

23561

Research Site, New Taipei City

24127

Research Site, Bergamo

26505

Research Site, Morgantown

27103

Research Site, Winston-Salem

28040

Research Site, Madrid

30625

Research Site, Hanover

32610

Research Site, Gainesville

33076

Research Site, Bordeaux

35016

Research Site, Las Palmas de Gran Canaria

37044

Research Site, Tours

40202

Research Site, Louisville

40447

Research Site, Taichung

40536

Research Site, Lexington

40705

Research Site, Taichung

42415

Research Site, Daegu

43203

Research Site, Columbus

44106

Research Site, Cleveland

44195

Research Site, Cleveland

45147

Research Site, Essen

55905

Research Site, Rochester

59037

Research Site, Lille

61469

Research Site, Gwangju

73011

Research Site, Chambéry

75020

Research Site, Paris

75571

Research Site, Paris

81362

Research Site, Kaohsiung City

84115

Research Site, Salt Lake City

85724

Research Site, Tucson

92868

Research Site, Orange

833401

Research Site, Kaohsiung City

02111

Research Site, Boston

02115

Research Site, Boston

02118

Research Site, Boston

30150-221

Research Site, Belo Horizonte

18618-687

Research Site, Botucatu

13083-894

Research Site, Campinas

60430-375

Research Site, Fortaleza

90110-270

Research Site, Porto Alegre

14051-040

Research Site, Ribeirão Preto

41253-190

Research Site, Salvador

04036-002

Research Site, São Paulo

05403-000

Research Site, São Paulo

K7L 3N6

Research Site, Kingston

M5B 1W8

Research Site, Toronto

H2X 3E4

Research Site, Montreal

G1R 3S1

Research Site, Québec

Unknown

Research Site, Montpellier

00168

Research Site, Roma

113-8431

Research Site, Bunkyō City

350-0495

Research Site, Iruma-Gun

181-8611

Research Site, Mitaka-shi

889-1692

Research Site, Miyazaki

466-8560

Research Site, Nagoya

466-8650

Research Site, Nagoya

565-0871

Research Site, Osaka

060-8648

Research Site, Sapporo

980-8574

Research Site, Sendai

162-8666

Research Site, Shinjuku-ku

1100 DD

Research Site, Amsterdam

9713 GZ

Research Site, Groningen

6229 HX

Research Site, Maastricht

6500 HB

Research Site, Nijmegen

02841

Research Site, Seoul

03080

Research Site, Seoul

04401

Research Site, Seoul

06973

Research Site, Seoul

134-727

Research Site, Seoul

08036

Research Site, Barcelona

BS10 5NB

Research Site, Bristol

SM5 1AA

Research Site, Carshalton

EX2 5DW

Research Site, Exeter

LE3 9QP

Research Site, Leicester

L7 8XP

Research Site, Liverpool

NW1 2BH

Research Site, London

NW3 2QG

Research Site, London

SE1 9RT

Research Site, London

SE5 9RS

Research Site, London

SW17 0QT

Research Site, London

M13 9WL

Research Site, Manchester

NE1 4LP

Research Site, Newcastle upon Tyne

NG5 1PB

Research Site, Nottingham

OX3 9DU

Research Site, Oxford

M6 8HD

Research Site, Salford

SG1 4AB

Research Site, Stevenage

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY